Printer Friendly

United States : TREVI THERAPEUTICS bagged $25m series B financing for raising Nalbuphine ER.

Trevi Therapeutics, a clinical stage biotechnology firm developing Nalbuphine ER for chronic pruritus conditions, declared about a Series B financing of $25m, headed TPG Biotech, the life science venture investment arm of TPG, with $15m financing at first closing.

Earlier, TPG Biotech injected in Company's angel investors, worth $12.8 million and the firm also contrives to utilise the funds for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis.

Jennifer L. Good, Trevi's President and Chief Executive Officer, said, "Since receiving Series A financing 18 months ago, the Company has generated compelling proof of concept safety and efficacy data for Nalbuphine ER in itch, including most recently in uremic pruritus.We continue to believe that the dual mechanism of action of nalbuphine is uniquely suited to treating many itch conditions."

This recent data established initial safety in renally impaired patients, and 12 out of the 14 patients dosed with Nalbuphine ER indicated a dose-dependent reduction in VAS scores measuring itch. We continue to believe that the dual mechanism of action of nalbuphine is uniquely suited to treating many itch conditions."

2014 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2014 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jun 7, 2014
Words:199
Previous Article:United States : OLDCASTLE Precast, WATER Harvesting inks Joint Venture contract.
Next Article:United States : 3 bid to offer service to Mid-Delta Airport.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters